CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 36 enrolled
Drug / intervention
Levodopa (delivered intravenously)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00467597
NCT00467597N/ACompleted
CompareCT.gov

Quantification of Levodopa Induced Dyskinesia in Parkinson Disease: Developing Objective Measures of Levodopa Induced Dyskinesia (Study One)

US Department of Veterans Affairs·observational·Posted Apr 30, 2007·Updated Nov 26, 2014

In Brief

An observational study evaluating Levodopa (delivered intravenously) for Dyskinesias and 2 related conditions. Completed, enrolled 36 participants across 1 site.

Detailed Summary

The ultimate goal of this proposal is to reduce dyskinesia in Parkinson's Disease (PD) patients. Dyskinesias are abnormal movements, often caused by the standard treatment for PD symptoms, levodopa. In this study, we will test if biochemical devices are equal to the clinical rating system in measuring dyskinesias.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDyskinesias, Movement Disorders, Parkinson Disease
CountriesUnited States
CollaboratorsOregon Health and Science University

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 30, 2007
Enrollment StartApr 1, 2006
Primary CompletionAug 1, 2008
Study CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 19.2 years ago

Interventions

Levodopa (delivered intravenously)drug

IV Levodopa is given from 09:00 to 11:00 am during the testing phase of the study. The IV Levodopa allows the researchers to watch one full "on" and "off" levodopa cycle while in the inpatient unit.